title: Contribution of progression of erosive damage in previously eroded joints in early rheumatoid arthritis trials: COBRA trial as an example.
abstract: OBJECTIVE
  In rheumatoid arthritis (RA) in the context of a drug trial, prevention of erosions in undamaged joints is often considered more important than prevention of progression in already damaged joints, although a clear rationale is lacking. The aim of this study is to evaluate the relative contribution of separate components of the erosion score of the modified Sharp/van der Heijde method in early RA.
  
  
  METHODS
  Different aspects of erosive damage were evaluated by their ability to discriminate between the 2 treatments in an early RA trial (the COBRA trial).
  
  
  RESULTS
  The contribution of progression of already eroded joints to the total erosion score clearly increased during the 1.5 years of the trial. When the periods 0-28, 28-56, and 56-80 weeks were analyzed separately, the erosion score showed a significant difference between the groups in the first 2 periods (P < 0.0001, P < 0.03, and P < 0.64, respectively). Similar differences were seen in rates of progression in previously eroded joints (P = 0.005, P = 0.003, P = 0.35). On the other hand, rates of progression in newly eroded joints showed no significant difference between the 2 treatment groups in the second and third period (P < 0.0001, P < 0.16, P < 0.87). Analyses on joint and patient level showed analogous results.
  
  
  CONCLUSIONS
  Subanalyses on progression rates in noneroded joints and already eroded joints can provide additional information. However, important information and discriminative strength may be lost when assessment is limited to the development of erosions in undamaged joints.
authors.affiliation: University of Maastricht, Maastricht, The Netherlands. kbru@sint.azm.nl
authors.forename: Karin
authors.initials: K
authors.lastname: Bruynesteyn
authors.forename: Désirée
authors.initials: D
authors.lastname: Van Der Heijde
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
authors.forename: Arco
authors.initials: A
authors.lastname: Verhoeven
authors.forename: Annelies
authors.initials: A
authors.lastname: Boonen
authors.forename: Sjef
authors.initials: S
authors.lastname: Van Der Linden
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D018450:Disease Progression; D006801:Humans; D007596:Joints / Q000473:pathology*; D011859:Radiography; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D018501:Antirheumatic Agents